Searching for new agents against lung cancer: the PROFILE 1014 and ALEX trials
What is the best sequence of treatment for NSCLC?
Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC
Continuing therapeutic progress in lung cancer
NSCLC: identifying patients most likely to relapse